Skip to main content
. 2020 Jul 17;111(8):2718–2725. doi: 10.1111/cas.14534

FIGURE 3.

FIGURE 3

FBXO22 predicts an outcome in patients with ER‐positive/HER2‐negative breast cancer. A, Relapse‐free survival of FBXO22‐positive and FBXO22‐negative cases in all ER‐positive/HER2‐negative breast cancers. B, Relapse‐free survival of FBXO22‐positive and FBXO22‐negative cases in luminal A–like (low Ki‐67) breast cancers. P‐values and hazard ratio (HRs) were calculated using a log‐rank test